CN102917704A - 可用作faah调节剂的噁唑衍生物 - Google Patents

可用作faah调节剂的噁唑衍生物 Download PDF

Info

Publication number
CN102917704A
CN102917704A CN2011800173842A CN201180017384A CN102917704A CN 102917704 A CN102917704 A CN 102917704A CN 2011800173842 A CN2011800173842 A CN 2011800173842A CN 201180017384 A CN201180017384 A CN 201180017384A CN 102917704 A CN102917704 A CN 102917704A
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
het
mono
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800173842A
Other languages
English (en)
Chinese (zh)
Inventor
杨志强
P.G.南特梅特
C.克里特索拉斯
K.P.穆尔
E.F.沙伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN102917704A publication Critical patent/CN102917704A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800173842A 2010-04-08 2011-04-04 可用作faah调节剂的噁唑衍生物 Pending CN102917704A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32199210P 2010-04-08 2010-04-08
US61/321992 2010-04-08
PCT/US2011/031040 WO2011126960A1 (en) 2010-04-08 2011-04-04 Oxazole derivatives useful as modulators of faah

Publications (1)

Publication Number Publication Date
CN102917704A true CN102917704A (zh) 2013-02-06

Family

ID=44763231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800173842A Pending CN102917704A (zh) 2010-04-08 2011-04-04 可用作faah调节剂的噁唑衍生物

Country Status (8)

Country Link
US (1) US9193697B2 (https=)
EP (1) EP2555772B1 (https=)
JP (1) JP2013523814A (https=)
CN (1) CN102917704A (https=)
AU (1) AU2011238487B2 (https=)
BR (1) BR112012023974A2 (https=)
CA (1) CA2793900A1 (https=)
WO (1) WO2011126960A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110804048A (zh) * 2019-11-08 2020-02-18 暨南大学 恶唑酮类化合物及其应用、faah的正电子药物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321288B1 (en) * 2008-08-04 2014-03-19 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of faah
US9006433B2 (en) 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
BR112019016241A2 (pt) 2017-02-08 2020-04-07 Bayer Cropscience Ag derivados de triazol e seu uso como fungicidas
CA3052519A1 (en) 2017-02-08 2018-08-16 Andreas Gortz Triazolethione derivatives
US20200045967A1 (en) 2017-02-08 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
KR20190115449A (ko) 2017-02-10 2019-10-11 바이엘 악티엔게젤샤프트 1-(페녹시-피리디닐)-2-(1,2,4-트리아졸-1-일)-에탄올 유도체를 포함하는 유해 미생물을 방제하기 위한 조성물
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena, Inc. COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
WO2025048475A1 (ko) * 2023-08-29 2025-03-06 고려대학교 세종산학협력단 옥사졸 유사체를 유효성분으로 포함하는 항노화 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
FR2921063B1 (fr) 2007-09-13 2009-12-11 Sod Conseils Rech Applic Ligands des recepteurs cannabinoides
CA2727245A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of faah
BR112012018913A2 (pt) * 2010-01-28 2017-06-20 Merck Sharp & Dohme "composição farmacêutica, e, uso da composição"

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110804048A (zh) * 2019-11-08 2020-02-18 暨南大学 恶唑酮类化合物及其应用、faah的正电子药物

Also Published As

Publication number Publication date
CA2793900A1 (en) 2011-10-13
EP2555772B1 (en) 2017-01-11
AU2011238487A1 (en) 2012-09-13
JP2013523814A (ja) 2013-06-17
AU2011238487B2 (en) 2015-10-01
US20130018048A1 (en) 2013-01-17
US9193697B2 (en) 2015-11-24
WO2011126960A1 (en) 2011-10-13
EP2555772A1 (en) 2013-02-13
BR112012023974A2 (pt) 2017-09-26
EP2555772A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
CN102917704A (zh) 可用作faah调节剂的噁唑衍生物
EP2321288B1 (en) Oxazole derivatives useful as inhibitors of faah
CN103153307A (zh) 用作faah调节剂的噁唑衍生物
US20110021531A1 (en) Oxazole derivatives useful as inhibitors of faah
JP2011523959A (ja) Ｆａａｈの阻害剤として有用なイミダゾール誘導体
CN102917707A (zh) 可用作faah调节剂的氮杂吲哚衍生物
CN102413694B (zh) 可用作faah调节剂和faah成像剂的咪唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170419

AD01 Patent right deemed abandoned